ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Zachs News Article mentioning Biogen and PMN ARFXF

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Jun 22, 2021 11:24pm

172 Views

Post# 33432438

RE:RE:Zachs News Article mentioning Biogen and PMN ARFXF

Indeed excellent News for PMN.to ARFXF! Imagine buying now and Biogen actually using PMN310. The SP will rise well above $1.00-$3.00. This is a Buy at the current SP and is a Long Term Investment (3-5 Years Exit).

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec